### Center for Cell Engineering Seventh Annual Retreat

# Celebrating the Opening of the Cell Therapy and Cell Engineering Facility

October 21, 2014 2:00 – 5:30 PM Zuckerman Auditorium

#### **SESSION I: STEM CELL THERAPY**

#### **Cell Therapy for Parkinson's Disease**

#### Lorenz Studer, MD

Director, Center for Stem Cell Biology Developmental Biology Program, MSK

#### Clinical Cord Blood Transplantation: Current State of the Art

#### Juliet N. Barker, MBBS

Director, Cord Blood Transplantation Program Department of Medicine, MSK

# Pluripotent-independent Reprogramming of Endothelial to Hematopoietic Cells by Vascular Induction

#### Shahin Rafii, MD

Director, Ansary Center for Stem Cell Therapeutics Weill Cornell Medical College

### Globin Gene Transfer for Thalassemia and Sickle Cell Disease

#### Farid Boulad, MD

Medical Director, Pediatric Day Hospital Department of Pediatrics, MSK

#### **SESSION II: T CELL THERAPY**

#### **CAR T Cells**

# The Many Roles of the Cell Therapy and Cell Engineering Facility

#### Isabelle Rivière, PhD

Director, Cell Therapy and Cell Engineering Facility Molecular Pharmacology & Chemistry Program, MSK

#### **CD19 CAR T Cell Therapy**

#### Renier Brentjens, MD, PhD

Director, Cellular Therapeutics Center Department of Medicine, MSK

#### **Mesothelin CAR T Cell Therapy**

#### Prasad S. Adusumilli, MD, FACS

Deputy Chief, Thoracic Service Department of Surgery, MSK

# **Enhancing the IQ of CAR T Cells Using the Synthetic Biology Tool Box**

#### Michael Jensen, MD

Director, Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, University of Washington

# The Design of Receptors and Cell Products for Cancer Immunotherapy

#### **Stanley Riddell, MD**

Member, Fred Hutchinson Cancer Research Center University of Washington School of Medicine

#### **TCR T Cells**

## **Engineering T Cells to Target Oncogenic Proteins: It Starts with the TCR**

#### Philip Greenberg, MD

Head, Immunology Program, Fred Hutchinson Cancer Research Center University of Washington School of Medicine

# Adoptive Immunotherapy with Transplant Donor or Third Party-derived EBV-specific T-cells for EBV-associated Malignancies

#### Richard O'Reilly, MD

Chair, Department of Pediatrics Chief, Pediatric Bone Marrow Transplant Service, MSK

#### **CLOSING REMARKS**

#### Michel Sadelain, MD, PhD

Director, Center for Cell Engineering Immunology Program, MSK

